Home > In process > Immunotherapies in progressive multiple sclerosis. > print

001     283186
005     20260114093356.0
024 7 _ |a 10.1016/B978-0-323-90887-0.00021-3
|2 doi
024 7 _ |a pmid:41526136
|2 pmid
024 7 _ |a 0072-9752
|2 ISSN
024 7 _ |a 2212-4152
|2 ISSN
037 _ _ |a DZNE-2026-00065
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Neziraj, Tradite
|b 0
245 _ _ |a Immunotherapies in progressive multiple sclerosis.
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier
295 1 0 |a Immunotherapies for Neurologic Diseases / ; : Elsevier, 2026, ; ISSN: 00729752 ; ISBN: 9780323908870 ; doi:10.1016/B978-0-323-90887-0.00021-3
300 _ _ |a 219 - 244
336 7 _ |a BOOK_CHAPTER
|2 ORCID
336 7 _ |a Book Section
|0 7
|2 EndNote
336 7 _ |a bookPart
|2 DRIVER
336 7 _ |a INBOOK
|2 BibTeX
336 7 _ |a Output Types/Book chapter
|2 DataCite
336 7 _ |a Contribution to a book
|b contb
|m contb
|0 PUB:(DE-HGF)7
|s 1768379511_5650
|2 PUB:(DE-HGF)
490 0 _ |a Handbook of Clinical Neurology
|v 214
520 _ _ |a Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, with both genetic and environmental risk factors. While traditionally, a relapsing and progressive disease course has been distinguished, it has increasingly become evident that elements of progression are the dominant factor for accumulating MS-related neurologic disability across all clinical courses and can be detected throughout the full disease trajectory in patients with MS. Therefore, defining the dominant pathophysiologic processes driving progression has become indispensable. Pathologic hallmarks of progressive MS include a compartmentalized inflammation within the central nervous system as well as associated neurodegenerative processes, finally leading to neuroaxonal and synaptic loss. Growing understanding of the pathophysiology has led to the development of an increasing number of targeted immunomodulatory treatment approaches for progressive MS. With the development of novel clinical trial designs and the evolution of clinical and paraclinical measures allowing accurate and rapid assessment of progression, new opportunities for personalized treatment regimens are likely to emerge.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef Book Series, PubMed, , Journals: pub.dzne.de
650 _ 7 |a B cells
|2 Other
650 _ 7 |a Immunomodulation
|2 Other
650 _ 7 |a Inflammation
|2 Other
650 _ 7 |a Multiple sclerosis
|2 Other
650 _ 7 |a Neurodegeneration
|2 Other
650 _ 7 |a Primary progressive MS
|2 Other
650 _ 7 |a Progression
|2 Other
650 _ 7 |a Immunologic Factors
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Immunotherapy: methods
|2 MeSH
650 _ 2 |a Multiple Sclerosis, Chronic Progressive: therapy
|2 MeSH
650 _ 2 |a Multiple Sclerosis, Chronic Progressive: immunology
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Immunologic Factors: therapeutic use
|2 MeSH
700 1 _ |a Kappos, Ludwig
|b 1
700 1 _ |a Pröbstel, Anne-Katrin
|0 P:(DE-2719)9003515
|b 2
|e Last author
|u dzne
773 _ _ |a 10.1016/B978-0-323-90887-0.00021-3
856 4 _ |u https://pub.dzne.de/record/283186/files/DZNE-2026-00065_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/283186/files/DZNE-2026-00065_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9003515
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1013045
|k AG Pröbstel
|l Clinical Neurology and Neuroimmunology
|x 0
980 _ _ |a contb
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1013045
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21